Biotech News

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

Jaguar Health (JAGX)Jaguar Health2026-11-02 14:00 ESTConference / presentation

Company remains sharply focused on its ongoing rare disease intestinal failure global development program for microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF) for crofelemer powder for oral solution, targeting an NDA filing for MVID mid-2027 SAN FRANCISCO, CA / ACCESS Newswire

Related news

JAGXJaguar Health2026-10-06 13:00 EST

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Intestinal Failure Panel Discussion at Pediatric Gastroenterology Conference in Abu Dhabi

JAGXJaguar Health2026-09-29 08:30 EST

Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

SCYXSCYNEXIS2026-10-29 12:00 EST

SCYNEXIS to Participate in the 3rd Annual Guggenheim Healthcare Innovation Conference

HROWHarrow, Inc.2026-03-18 11:00 EST

Harrow Announces Three Abstracts Accepted for Presentation at ASCRS 2026 Annual Meeting

SCYXSCYNEXIS2026-10-21 20:05 EST

SCYNEXIS to Feature SCY-247 in a Pipeline Presentation at IDWeek

HROWHarrow, Inc.2026-05-27 11:00 EST

Harrow to Present at William Blair’s 46th Annual Growth Stock Conference

VIRXViracta Therapeutics2024-09-05 15:32 EST

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

IBRXImmunityBio2026-03-17 11:30 EST

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include ANKTIVA® Plus BCG for Patients With BCG-Unresponsive NMIBC With Papillary-Only Disease

IBRXImmunityBio2026-07-29 22:45 EST

ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer

ALZNAlzamend Neuro2026-03-26 12:00 EST

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

View all latest news

Jaguar Health

Plant-Derived Gastrointestinal Medicines Jaguar Health develops prescription medicines derived from plants for serious gastrointestinal disorders. Its Napo subsidiaries lead development and commercialization of crofelemer for rare intestinal-failure conditions. Crofelemer Mechanism Crofelemer is a plant-derived antisecretory medicine...

Recent company news

JAGXJaguar Health2026-11-06 21:15 EST

Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders

JAGXJaguar Health2026-11-02 14:00 EST

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

JAGXJaguar Health2026-10-21 13:00 EST

Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder

JAGXJaguar Health2026-10-14 20:15 EST

Jaguar Health Provides Update Regarding Special Stock Dividend

JAGXJaguar Health2026-10-14 13:00 EST

Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer

Stock data

Close: 0.41 USD
Market cap: 2.12M USD
Exchange: NASDAQ
Sector: Biopharma
Location: San Francisco, California